AIDS
Acute Immunodeficiency Syndrome
ART
Antiretroviral Therapy
BAI
Beck Anxiety Inventory
BDI
Beck Depression Inventory
BIC/FTC/TAF
Bictegravir/Emtricitabine/Tenofovir alafenamide
CDC
Center for Disease Control
DDIs
Drug-Drug Interactions
DHHS
Department of Health and Human Services
DTG/FTC/TAF
Dolutegravir/Emtricitabine/Tenofovir alafenamide
DTG/3TC
Dolutegravir/Lamivudine
eCRF
Electronic Case Report Forms
EACS
European AIDS Clinical Society
EDTA
Ethylenediaminetetraacetic acid
eGFR
estimated Glomerular Filtration Rate
ELISA
Enzyme-Linked Immunosorbent Assay
EVG/c
Elvitegravir/cobicistat
FDA
Food and Drug Administration
HDL
High-Density Lipoprotein
HIV
Human Immunodeficiency Virus
HPLC-UV
High-Performance Liquid Chromatography-Ultra Violet
IAS-USA
International Antiviral Society-USA
IGRA
Interferon Gamma Release Assay
INSTIs
Integrase Inhibitors
IRIS
Immune Reconstitution Inflammatory Syndrome
LDL
Low-Density Lipoprotein
MDRD
Modification of Diet in Renal Disease
NGS
Next Generation Sequencing
NNRTI
Non-Nucleoside Reverse Transcriptase Inhibitor
NRTIs
Nucleoside Reverse Transcriptase Inhibitors
OCT2
Organic Cation Transporter 2
OI
Opportunistic Infections
PBMCs
Peripheral Blood Mononuclear Cells
PDVF
Protocol-Defined Virological Failure
PLWH
People Living With HIV
PML
progressive multifocal leukoencephalopathy
PROs
Patient-Reported Outcomes
RAM
Resistance-Associated Mutations
SNAE
Serious Non-AIDS Defining Event
SAEs
Serious Adverse Events
TDM
Therapeutic Drug Monitoring
TDR
Transmitted Drug Resistance
WHO
world health organization
Comments (0)